• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enveric Biosciences Inc (NQ: ENVB )

    0.4700 -0.0150 (-3.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 296,929
    Open 0.5000
    Bid (Size) 0.4900 (5)
    Ask (Size) 0.5000 (16)
    Prev. Close 0.4850
    Today's Range 0.4250 - 0.5046
    52wk Range 0.4100 - 3.898
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
    From Enveric Biosciences
    Via Business Wire
    New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
    Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property

    Performance

    YTD
    -62.70%
    -62.70%
    1 Month
    -25.54%
    -25.54%
    3 Month
    -46.63%
    -46.63%
    6 Month
    -56.88%
    -56.88%
    1 Year
    -83.62%
    -83.62%

    More News

    Read More
    Enveric Biosciences Announces Patent Granted for Drug Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
    From Enveric Biosciences
    Via Business Wire
    Enveric Biosciences to Participate in BIO International Convention 2024
    From Enveric Biosciences
    Via Business Wire
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
    Via InvestorPlace
    'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
    Via Benzinga
    Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
    From Enveric Biosciences
    Via Business Wire
    Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
    Via Benzinga
    Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
    From Enveric Biosciences
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
    From Enveric Biosciences
    Via Business Wire
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Exposures Glyphosate
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
    Via InvestorPlace
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
    Via Benzinga
    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
    From Enveric Biosciences
    Via Business Wire
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Nasdaq Down 100 Points; US Housing Starts Surge In February
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.